DE602005026785D1 - Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom - Google Patents

Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Info

Publication number
DE602005026785D1
DE602005026785D1 DE602005026785T DE602005026785T DE602005026785D1 DE 602005026785 D1 DE602005026785 D1 DE 602005026785D1 DE 602005026785 T DE602005026785 T DE 602005026785T DE 602005026785 T DE602005026785 T DE 602005026785T DE 602005026785 D1 DE602005026785 D1 DE 602005026785D1
Authority
DE
Germany
Prior art keywords
treatment
insulin resistance
prevention
type
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026785T
Other languages
English (en)
Inventor
Willem Ferdinand Nieuwenhuizen
Aloysius Maria Havekes
Josephus Jan Emeis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34975255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005026785(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP04075848A external-priority patent/EP1576894A1/de
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Publication of DE602005026785D1 publication Critical patent/DE602005026785D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE602005026785T 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom Active DE602005026785D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075848A EP1576894A1 (de) 2004-03-16 2004-03-16 Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS
EP04077088 2004-07-19
PCT/NL2005/000193 WO2005087023A1 (en) 2004-03-16 2005-03-15 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome

Publications (1)

Publication Number Publication Date
DE602005026785D1 true DE602005026785D1 (de) 2011-04-21

Family

ID=34975255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026785T Active DE602005026785D1 (de) 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Country Status (7)

Country Link
US (3) US20070207983A1 (de)
EP (1) EP1729597B1 (de)
JP (1) JP5154218B2 (de)
AT (1) ATE500752T1 (de)
AU (1) AU2005220692A1 (de)
DE (1) DE602005026785D1 (de)
WO (1) WO2005087023A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US20090117198A1 (en) 2006-05-31 2009-05-07 Hiroshi Kawakami Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level
EP2167485B1 (de) 2007-05-31 2015-09-30 Genzyme Corporation Glucosylceramidsynthaseinhibitoren vom 2-acylaminopropoanoltyp
MX2010003603A (es) 2007-10-05 2010-06-02 Genzyme Corp Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
MX2011003517A (es) 2008-10-03 2011-05-25 Genzyme Corp Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol.
US8178515B2 (en) * 2008-10-08 2012-05-15 Nucitec S.A. De C.V. β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof
WO2010131718A1 (ja) * 2009-05-13 2010-11-18 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP6169978B2 (ja) * 2012-01-25 2017-07-26 株式会社Ｊ−オイルミルズ スフィンゴイド塩基を含む抽出物の製造方法
US9492466B2 (en) 2012-06-14 2016-11-15 Nucitec S.A. De C.V. Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP3157531B2 (ja) * 1991-03-08 2001-04-16 昭和産業株式会社 血中コレステロール低下剤
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
DE69828603T2 (de) * 1997-04-10 2005-12-29 Kirin Beer K.K. Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittels zur Behandlung von Autoimmunkrankheiten
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
EP1049477A1 (de) * 1997-12-30 2000-11-08 A+ Science Invest AB Galactosylceramide, glucosylceramide, lactosylceramide, und spezifische fänger für diese zur verwendung in der prophylaxe oder therapie der prädiabetes, diabetes und/oder damit zusammenhängender komplikationen
EP1053243B1 (de) * 1998-02-12 2011-03-30 Emory University Sphingolipid-derivate und verfahren zu deren verwendung
WO2000050574A1 (en) * 1999-02-24 2000-08-31 Johns Hopkins University Compositions and methods for modulating serum cholesterol
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) * 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
WO2001060807A1 (en) * 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2001072701A1 (en) * 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
JP2002226394A (ja) * 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
JP4958339B2 (ja) * 2001-03-21 2012-06-20 雪印メグミルク株式会社 脂質代謝改善剤
CN1516592A (zh) * 2001-06-18 2004-07-28 �����Ǽ���&������Դ���޹�˾ 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4568464B2 (ja) * 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
DE602004020316D1 (de) * 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
JP4585172B2 (ja) * 2003-01-31 2010-11-24 森永乳業株式会社 骨形成促進剤
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP4341891B2 (ja) * 2003-03-05 2009-10-14 森永乳業株式会社 血糖降下組成物
JP2006514671A (ja) * 2003-03-07 2006-05-11 コリア アトミック エナジー リサーチ インスティテュート フィトスフィンゴシンまたはその誘導体を含む組成物

Also Published As

Publication number Publication date
JP5154218B2 (ja) 2013-02-27
US20090203651A1 (en) 2009-08-13
ATE500752T1 (de) 2011-03-15
US20070207983A1 (en) 2007-09-06
EP1729597A1 (de) 2006-12-13
JP2007529507A (ja) 2007-10-25
WO2005087023A1 (en) 2005-09-22
US20110003772A1 (en) 2011-01-06
EP1729597B1 (de) 2011-03-09
AU2005220692A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
ATE500752T1 (de) Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
TW200602043A (en) Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
TW200730540A (en) Novel peptide compounds
RU2010143817A (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
MY142807A (en) Benzimidazole derivative and use thereof.
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
DE502004002556D1 (de) Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
BR0317703A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
MY151295A (en) Pyrimidyl indoline compound
MY151072A (en) Heteroaryl derivative
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
GEP20104882B (en) Age inhibitors
DE602004030004D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
WO2008096769A1 (ja) 置換されたセルコスポラミド誘導体を含有する医薬
WO2007033039A3 (en) Proteasome inhibiting beta lactam compounds
BRPI0512086A (pt) composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
WO2006002802A8 (en) Phenyl derivatives comprising an acetylene group
UA94579C2 (ru) Анетолдитиолтион и другие дитиолтионы для лечения состояний, связанных с дисфункцией нейротрансмисии моноамина
EP2055188A4 (de) Polyphenolgehaltsteigerndes mittel für pflanze
MX2009006094A (es) Uso de derivados canfolenicos como ingredientes fragantes en perfumeria y saborizacion.